International Assets Investment Management LLC Invests $487.59 Million in Becton, Dickinson and Company (NYSE:BDX)

International Assets Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 202,236 shares of the medical instruments supplier’s stock, valued at approximately $487,590,000. International Assets Investment Management LLC owned 0.07% of Becton, Dickinson and Company at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at about $229,000. Brookstone Capital Management raised its position in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brookstone Capital Management now owns 11,725 shares of the medical instruments supplier’s stock valued at $2,901,000 after purchasing an additional 139 shares during the period. Fifth Third Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $542,000. Indiana Trust & Investment Management CO boosted its holdings in Becton, Dickinson and Company by 126.9% in the 1st quarter. Indiana Trust & Investment Management CO now owns 236 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 132 shares during the period. Finally, Capital Asset Advisory Services LLC raised its holdings in Becton, Dickinson and Company by 45.2% during the first quarter. Capital Asset Advisory Services LLC now owns 1,484 shares of the medical instruments supplier’s stock valued at $365,000 after acquiring an additional 462 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BDX. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Trading Down 0.8 %

Shares of BDX opened at $238.62 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The company’s fifty day simple moving average is $237.33 and its 200-day simple moving average is $235.16. The company has a market cap of $68.96 billion, a P/E ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the previous year, the business earned $2.96 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.